Amgen's MariTide cardiovascular outcomes trial surfaces; OASIS pediatric migraine results hold

Amgen reports a new Phase 3 cardiovascular outcomes trial for maridebart cafraglutide (MariTide) and keeps its completed pediatric erenumab migraine study on the books.

Amgen's latest records show one newly surfaced large cardiovascular trial alongside its previously reported pediatric migraine results.

"Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity" (MARITIME-CV), a Phase 3 trial sponsored by Amgen, is listed as active not recruiting. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.¹ The study plans to enroll 12800 participants (estimated)¹, with primary completion estimated for 2028-06-30.
"Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine" (OASIS PEDIATRIC [CM]), a Phase 3 trial of erenumab (AMG 334, Aimovig) sponsored by Amgen with Novartis as collaborator, remains listed as completed with results first posted on 2026-10-28. The study evaluated the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine, enrolling 284 participants (actual).² As pre-specified in the Statistical Analysis Plan (SAP), only results from adolescents are presented.²

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.